A year ago, we wrote about an important change in Alzheimer’s diagnosis: blood tests were becoming a practical way to help identify biological signs associated with the disease. Researchers are now studying whether some of those same blood biomarkers can help predict who may eventually develop memory and thinking problems. Before these studies are complete, however, people without symptoms are increasingly seeking out these tests on their own which raises an understandable question:

If a blood test shows signs associated with Alzheimer’s disease, does that mean dementia is coming?

The answer, at least for now, is: not necessarily.

These tests are giving doctors and researchers more information than ever before. But they still cannot reliably tell an individual family exactly what will happen, when symptoms might begin, or how quickly a person may change. Understanding that distinction is especially important for caregivers, because test results can easily feel more certain than they really are.

What Alzheimer’s blood tests were designed to do

Current FDA-cleared Alzheimer’s blood tests are designed to help evaluate people who are already experiencing memory, thinking, or other cognitive changes. The tests look for biological markers associated with Alzheimer’s disease. One of the most closely watched is called p-tau217, a form of tau protein that is strongly associated with amyloid buildup in the brain.

In someone who is already having symptoms, that information can help doctors answer a useful question:

Are Alzheimer’s-related brain changes likely contributing to the problems we are seeing?

That can make blood testing a valuable part of the diagnostic process.

But that is different from asking:

Will this person, who is currently functioning normally, develop dementia in the future?

That second question is much harder.

Why researchers think these tests may eventually help predict risk

Alzheimer’s-related changes in the brain can begin many years before obvious memory problems appear. Because p-tau217 appears to track closely with those changes, researchers are studying whether blood levels of the protein can help estimate a person’s future risk.

A large study published in 2026 followed more than 2,600 cognitively healthy older adults. Researchers found that people with very high p-tau217 levels were more likely to develop cognitive impairment over time. Among those in the highest-risk group, researchers estimated about a 38 percent chance of developing memory or thinking problems within five years. That is a meaningful increase in risk. But it is not a guarantee.

It also means that most people in that group did NOT develop cognitive impairment during those five years.

The study also found higher estimated risk over longer periods, but researchers cautioned that those longer-term estimates were based on fewer people and should not yet be used to make precise predictions for individuals. That is the key difference families need to understand.

A test may show that someone is at higher risk without being able to tell us what will happen to that particular person.

A positive result is not a countdown to dementia

An elevated Alzheimer’s biomarker can sound frightening.

It may be easy to hear:

“Changes associated with Alzheimer’s are present.”

and immediately translate that into:

“Dementia is coming soon.”

Those statements are not the same.

A blood test cannot currently tell a family:

• whether dementia will definitely develop,
• when noticeable symptoms might begin,
• how quickly changes would progress,
• or how much help the person may eventually need.

One comparison sometimes used by experts is cholesterol. High cholesterol can tell us that a person has an increased risk of heart disease. It cannot tell us whether that person will have a heart attack next year.

In a similar way, Alzheimer’s blood biomarkers are beginning to give doctors more information about risk without providing a reliable timetable for an individual life. That distinction matters a great deal when families are trying to make decisions.

What this means when you are caring for someone you love

Families are rarely thinking about biomarkers in the abstract. They are trying to decide what is safe and what kind of help someone needs.

You may be wondering:

Is Mom still safe to drive?

Can Dad manage his medications?

Is my spouse still able to handle the household finances?

Can they continue living alone?

Is it time to bring in more help?

A blood test cannot answer those questions by itself. Those decisions still depend on the person’s actual abilities, judgment, safety, and day-to-day functioning.

For caregivers, that means continuing to pay close attention to meaningful changes in everyday life. You may notice things such as getting lost in familiar places, missing medications, leaving bills unpaid, struggling with routines that were once automatic, repeating the same questions, making unusually poor decisions, or having increasing difficulty managing ordinary tasks. Those changes matter because they show how cognition is affecting real life.

A blood biomarker may help a doctor understand why those changes are happening. It should not replace careful attention to the changes themselves.

One blood result does not tell the whole story

Another important part of the current science is that not every test result is equally clear. Very high or very low biomarker levels may be easier to interpret than results that fall somewhere in the middle. False positives and false negatives can also occur, and other medical conditions may sometimes affect results. That is why doctors do not interpret Alzheimer’s blood tests in isolation. A full evaluation may also include cognitive testing, medical history, neurological assessment, brain imaging, or other biomarker testing. For families, the takeaway is simple:

A blood test is one piece of a dementia evaluation. It is not the whole diagnosis.

What if someone has no symptoms but wants the test?

Wanting more information is understandable. But current expert guidance does not recommend routine Alzheimer’s blood-biomarker screening for people who have no cognitive symptoms. The reason is not that the tests are meaningless. It is that doctors still do not know how to translate an abnormal result into a reliable prediction for one healthy person.

Before pursuing testing, it can be helpful to ask:

What question are we hoping this test will answer?

If the answer is:

“Will I definitely develop Alzheimer’s?”

today’s testing cannot provide that certainty.

If the answer is:

“Do I have a biomarker associated with increased future risk?”

the test may be able to provide some information, but that information comes with uncertainty that families need to understand before testing.

What families can do today

If someone you love is showing meaningful changes in memory, thinking, judgment, or everyday function, the most useful next step is still a complete medical evaluation. Blood biomarkers may now be part of that process.

If your loved one already has an abnormal Alzheimer’s blood test, ask the doctor how the result fits with the rest of the picture.

Does it match the person’s symptoms?

What did cognitive testing show?

Are additional tests needed?

What changes should the family be watching for?

And regardless of biomarker status, supporting overall health remains worthwhile. Regular physical activity, good nutrition, social connection, healthy sleep, and management of conditions such as high blood pressure and diabetes all support brain health. These steps do not guarantee that Alzheimer’s can be prevented. But research continues to show that overall health can influence how well the brain functions and how people cope with age-related and disease-related changes.

Why this research is still hopeful

The reason researchers want to identify Alzheimer’s-related changes earlier is simple: earlier detection could eventually create a much larger window for treatment. Today, blood tests are better at identifying biological changes than they are at telling us exactly what those changes mean for one person’s future. But that gap is narrowing.

Researchers are learning more about which biomarkers matter most, how to interpret different levels, and how early biological changes relate to later symptoms. At the same time, treatments are moving earlier in the disease process. If future therapies are able to delay or prevent symptoms before cognitive decline begins, identifying risk years earlier could become enormously valuable.

For now, families do not need to treat an abnormal blood test like a clock that has started counting down. It is information. Sometimes very important information. But caregiving decisions still depend on the whole picture: the changes you are seeing, your loved one’s abilities, their health, their wishes, and the guidance of the professionals caring for them.